Pfizer Says Its COVID Vaccine Provides Full Protection to Adolescents

Newest Coronavirus Information

News Picture: Pfizer Says Its COVID Vaccine Provides Full Protection to Adolescents

MONDAY, Nov. 22, 2021 (HealthDay Information)

Pfizer Inc. mentioned Monday that its coronavirus vaccine offers long-term safety in youth ages 12-15, in accordance with knowledge from an organization medical trial that included greater than 2,200 contributors.

In an organization medical trial that included greater than 2,200 adolescents, getting two doses of the vaccine was 100% efficient in opposition to the coronavirus from seven days to 4 months after the second shot, Pfizer mentioned in a news release.

There have been 30 confirmed symptomatic COVID-19 circumstances within the trial, and all have been within the placebo group.

In August, the U.S. Meals and Drug Administration granted full approval of the vaccine to be used in folks aged 16 and older. The vaccine has been granted emergency use authorization for youth ages 12-15, however Pfizer will submit this new knowledge to the FDA because it seeks full approval for that age group.

“As the worldwide well being group works to extend the variety of vaccinated folks world wide, these extra knowledge present additional confidence in our vaccine’s security and effectiveness profile in adolescents,” Pfizer CEO Albert Bourla mentioned. “That is particularly vital as we see charges of COVID-19 climbing on this age group in some areas, whereas vaccine uptake has slowed.”

On Friday, the FDA approved Pfizer and Moderna COVID-19 vaccine booster photographs for all adults aged 18 or older.

Extra data

Go to the U.S. Meals and Drug Administration for extra on COVID vaccines.

SOURCE: Pfizer INc., information launch, Nov. 22, 2021

Robert Preidt

MedicalNews
Copyright © 2021 HealthDay. All rights reserved.

Leave a Reply